Brian K Halak
CIK 1354718 · last filed 2023-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$287.99M
Companies
18
Total Filings
81
Lifetime Open-Market Net
$78.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALIMERA SCIENCES INC (ALIM) Delisted | Director | 327 | $5.54 | $1.8K | $0 | 15 | 2023-01-06 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 45,665 | $38.22 | $1.75M | -$19.89M | 10 | 2018-11-06 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 959,256 | — | — | -$4.77M | 8 | 2016-04-27 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | 10%+ Owner | 3,553,322 | — | — | $20.65M | 1 | 2015-05-06 |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 16,529 | — | — | $7.06M | 2 | 2014-11-18 |
| ATRA | 10%+ Owner | 636 | $8.45 | $5.4K | $141.8K | 1 | 2014-10-21 |
| VCYT | 10%+ Owner | 5,826,588 | $47.22 | $275.13M | $0 | 2 | 2014-09-12 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 1,987,049 | — | — | $0 | 1 | 2014-03-17 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | 10%+ Owner | 97,377 | — | — | $17.01M | 10 | 2014-02-14 |
| TNDM | 10%+ Owner | 318,906 | $22.38 | $7.14M | $0 | 2 | 2013-11-19 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 15,731 | — | — | $8.00M | 1 | 2013-07-16 |
| ESPR | 10%+ Owner | 1,786,012 | $3.18 | $5.68M | $4.00M | 1 | 2013-07-02 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 159,896 | — | — | $0 | 3 | 2013-01-18 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 296,742 | — | — | $18.29M | 12 | 2011-12-22 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 13,958 | $0.08 | $1.1K | $12.11M | 1 | 2011-11-21 |
| ZOGENIX, INC. (ZGNX) Delisted | 10%+ Owner | 21,156 | $26.68 | $564.4K | $16.40M | 2 | 2011-09-20 |
| VNDA | Director | 7,276 | $5.00 | $36.4K | $0 | 4 | 2010-03-30 |
| Volcano Corp (VOLC) Delisted | 10%+ Owner | 60,133 | — | — | -$53.3K | 3 | 2008-06-09 |
Recent Filings · Page 4 of 9
81 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-03-21 | — | Disp (D) | −3,050,921 | -$42.71M | |
| 2014-03-17 | Achaogen, Inc. (AKAO) Delisted | Conv (C) | +2,020,939 | $0 | EDGAR |
| 2014-02-14 | CADENCE PHARMACEUTICALS INC (CADX) Delisted | Mixed | +71,813 | -$47 | EDGAR |
| 2014-02-04 | Dicerna Pharmaceuticals Inc (DRNA) Delisted | Conv (C) | +1,765,711 | $0 | EDGAR |
| 2013-11-19 | TNDM | Mixed | +3,243,448 | $0 | EDGAR |
| 2013-11-19 | TNDM | Mixed | +3,243,448 | $0 | EDGAR |
| 2013-11-04 | VCYT | Conv (C) | +3,086,024 | $0 | EDGAR |
| 2013-09-30 | Evoke Pharma Inc (OMED) Delisted | Conv (C) | +1,133,333 | $0 | EDGAR |
| 2013-07-25 | — | Buy (P) | +995,618 | $6.00M | |
| 2013-07-16 | Ocera Therapeutics, Inc. (TZYM) Delisted | Buy (P) | +1,327,491 | $8.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.